ALMIRALL, S.A. «12345...» Page 2 out of 16 19/02/2024 06:54 ALMIRALL, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del segundo semestre de 2023 Register number: 26608 19/02/2024 06:52 ALMIRALL, S.A. On business and financial situation Presentation FY2023 Financial Results Register number: 26607 19/02/2024 06:49 ALMIRALL, S.A. Annual financial reports and audit reports La sociedad remite el Informe Financiero Anual del ejercicio 2023 Register number: 26606 19/02/2024 06:49 ALMIRALL, S.A. Other relevant information Webcast with analysts and institutional investors: Presentation of FY 2023 Financial Results Register number: 26605 19/02/2024 06:47 ALMIRALL, S.A. Annual report on directors´ remunerations La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2023 Register number: 26604 19/02/2024 06:47 ALMIRALL, S.A. Annual corporate governance report La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2023 Register number: 26603 04/01/2024 17:36 ALMIRALL, S.A. Liquidity and counterparty agreements Operaciones del contrato de liquidez durante el cuarto trimestre de 2023 Register number: 26061 12/12/2023 07:59 ALMIRALL, S.A. On business and financial situation Almirall and etherna enter into a multi-target alliance to develop mRNA-based therapies in medical dermatology Register number: 25748 17/11/2023 11:55 ALMIRALL, S.A. On business and financial situation Almirall receives European Commission approval of EBGLYSS® (lebrikizumab) for moderate-to-severe atopic dermatitis Register number: 25456 09/11/2023 06:59 ALMIRALL, S.A. On business and financial situation Almirall files Nine Months 2023 Results Presentation Register number: 25298 Page 2 out of 16 «12345...»